ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,640Medicare Part D Prescriptions Filled, Including Refills

Rank: 188 out of 783

$508K Total Retail Price of All Prescriptions

Rank: 257 out of 783

481 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
24% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 481 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

9% of this provider’s 481 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

2% of this provider’s 8,948 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$53 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
SIMVASTATIN 502 480 1 3
LEVOTHYROXINE SODIUM 320 291 2 1
WARFARIN SODIUM 297 285 3 10
FUROSEMIDE 282 277 4 7
LISINOPRIL 279 244 5 4
AMLODIPINE BESYLATE 273 259 6 5
OMEPRAZOLE 229 199 7 6
ATORVASTATIN CALCIUM 206 200 8 11
HYDROCODONE-ACETAMINOPHEN 199 196 S3 9 2
METFORMIN HCL 194 194 10 8
METOPROLOL TARTRATE 172 162 11 9
GLIPIZIDE 164 163 12 71
SERTRALINE HCL 160 146 13 22
DOXAZOSIN MESYLATE 158 158 14 87
ATENOLOL 156 156 15 17
LOSARTAN POTASSIUM 154 148 16 18
HYDROCHLOROTHIAZIDE 152 130 17 12
PRAVASTATIN SODIUM 150 140 18 14
ALENDRONATE SODIUM 144 131 19 25
ENALAPRIL MALEATE 136 133 20 68
DONEPEZIL HCL 133 123 21 24
POTASSIUM CHLORIDE 132 117 22 16
LOVASTATIN 102 90 23 58
TAMSULOSIN HCL 100 100 24 26
METOPROLOL SUCCINATE 94 93 25 13
CARVEDILOL 90 85 26 21
ALLOPURINOL 83 81 27 31
PAROXETINE HCL 83 82 27 69
NEXIUM 81 80 29 28
LOSARTAN-HYDROCHLOROTHIAZIDE 79 79 30 53
SPIRONOLACTONE 71 67 31 57
NAMENDA 71 61 31 32
TRAMADOL HCL 70 69 33 20
HUMULIN 70-30 69 63 34 211
CYCLOBENZAPRINE HCL 69 63 R 34 63
KLOR-CON M20 68 52 36 48
CIPROFLOXACIN HCL 65 63 37 62
FENTANYL 65 65 S2 37 65
LANTUS 65 53 37 38
GABAPENTIN 62 57 40 15
TERAZOSIN HCL 62 58 40 130
ADVAIR DISKUS 60 51 42 50
DIOVAN 60 56 42 49
DILTIAZEM 24HR ER 59 59 44 122
VESICARE 59 59 44 188
POLYETHYLENE GLYCOL 3350 54 54 46 43
TRIAMTERENE-HYDROCHLOROTHIAZID 51 45 47 173
FINASTERIDE 50 50 48 127
RANITIDINE HCL 50 49 48 44
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 6, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.